Answers are grounded in this paper and cite their sources.
Findings reveal DENND2D as a prognostic biomarker in glioma, suggesting potential therapeutic strategies against immunotherapy resistance.
DENND2D acts as an oncogene in glioma, driving aggressiveness and shaping an immunosuppressive microenvironment. It represents a novel prognostic biomarker and therapeutic target for overcoming immunotherapy resistance.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: